172 related articles for article (PubMed ID: 22454423)
21. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
22. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.
Moyer AM; Sun Z; Batzler AJ; Li L; Schaid DJ; Yang P; Weinshilboum RM
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):811-21. PubMed ID: 20200426
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
[TBL] [Abstract][Full Text] [Related]
24. Determination of O⁶-methylguanine DNA methyltransferase promoter methylation in non-small cell lung cancer.
Ekim M; Caner V; Büyükpınarbaşılı N; Tepeli E; Elmas L; Bağcı G
Genet Test Mol Biomarkers; 2011 May; 15(5):357-60. PubMed ID: 21288129
[TBL] [Abstract][Full Text] [Related]
25. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
Niu N; Schaid DJ; Abo RP; Kalari K; Fridley BL; Feng Q; Jenkins G; Batzler A; Brisbin AG; Cunningham JM; Li L; Sun Z; Yang P; Wang L
BMC Cancer; 2012 Sep; 12():422. PubMed ID: 23006423
[TBL] [Abstract][Full Text] [Related]
26. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
Hoffmann AC; Kaifi JT; Vallböhmer D; Yekebas E; Grimminger P; Leers JM; Izbicki JR; Hölscher AH; Schneider PM; Metzger R; Brabender J
J Surg Oncol; 2009 Oct; 100(5):414-7. PubMed ID: 19653236
[TBL] [Abstract][Full Text] [Related]
27. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Wu PF; Kuo KT; Kuo LT; Lin YT; Lee WC; Lu YS; Yang CH; Wu RM; Tu YK; Tasi JC; Tseng HM; Tseng SH; Cheng AL; Lin CH
Lung Cancer; 2010 Jun; 68(3):484-90. PubMed ID: 19740564
[TBL] [Abstract][Full Text] [Related]
28. A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer.
Lee SY; Choi JE; Jeon HS; Hong MJ; Choi YY; Kang HG; Yoo SS; Lee EB; Jeong JY; Lee WK; Lee J; Cha SI; Kim CH; Kim YT; Jheon S; Son JW; Park JY
Ann Oncol; 2015 Jun; 26(6):1142-1148. PubMed ID: 25716425
[TBL] [Abstract][Full Text] [Related]
29. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
[TBL] [Abstract][Full Text] [Related]
30. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk.
Qian B; Zhang H; Zhang L; Zhou X; Yu H; Chen K
Lung Cancer; 2011 Aug; 73(2):138-46. PubMed ID: 21195504
[TBL] [Abstract][Full Text] [Related]
31. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Cuffe S; Azad AK; Qiu X; Qiu X; Brhane Y; Kuang Q; Marsh S; Savas S; Chen Z; Cheng D; Leighl NB; Goss G; Laurie SA; Seymour L; Bradbury PA; Shepherd FA; Tsao MS; Chen BE; Xu W; Liu G
Cancer Epidemiol; 2016 Apr; 41():50-6. PubMed ID: 26816351
[TBL] [Abstract][Full Text] [Related]
32. Relationship between deficits in overall quality of life and non-small-cell lung cancer survival.
Sloan JA; Zhao X; Novotny PJ; Wampfler J; Garces Y; Clark MM; Yang P
J Clin Oncol; 2012 May; 30(13):1498-504. PubMed ID: 22454418
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
34. Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.
Hollen PJ; Gralla RJ; Rittenberg CN
Support Care Cancer; 2004 Nov; 12(11):767-73. PubMed ID: 15206013
[TBL] [Abstract][Full Text] [Related]
35. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer.
Wang Y; Gudikote J; Giri U; Yan J; Deng W; Ye R; Jiang W; Li N; Hobbs BP; Wang J; Swisher SG; Fujimoto J; Wistuba II; Komaki R; Heymach JV; Lin SH
Clin Cancer Res; 2018 Jan; 24(2):341-350. PubMed ID: 29030353
[No Abstract] [Full Text] [Related]
36. Lung cancer risk and variation in MGMT activity and sequence.
Povey AC; Margison GP; Santibáñez-Koref MF
DNA Repair (Amst); 2007 Aug; 6(8):1134-44. PubMed ID: 17569600
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
[TBL] [Abstract][Full Text] [Related]
38. Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors.
Rausch SM; Clark MM; Patten C; Liu H; Felten S; Li Y; Sloan J; Yang P
Cancer; 2010 Sep; 116(17):4103-13. PubMed ID: 20564140
[TBL] [Abstract][Full Text] [Related]
39. MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G; Dubois F; Fouret P; Antoine M; Brosseau S; Bergot E; Beau-Faller M; Gounant V; Brambilla E; Debieuvre D; Molinier O; Galateau-Sallé F; Mazieres J; Quoix E; Pujol JL; Moro-Sibilot D; Langlais A; Morin F; Westeel V; Zalcman G
Oncotarget; 2017 Jan; 8(3):4313-4329. PubMed ID: 28008145
[TBL] [Abstract][Full Text] [Related]
40. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
